Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

BPTH $1.18 0.0800 +7.27%
ONCS $5.77 0.3900 +7.25%
CERU $4.32 0.2900 +7.20%
NYMX $2.47 0.1200 +5.11%
APRI $1.78 0.0800 +4.71%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

ADXS $13.62 -1.1800 -7.97%
IDRA $2.79 -0.2300 -7.62%
CYTR $2.29 -0.1700 -6.91%
FGEN $22.84 -1.6600 -6.78%
ONCY $0.56 -0.0400 -6.67%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | Next > | Last >>

Medicare Bundled Payment Gains Momentum With Hospitals, Nursing Homes

(Forbes) Aug 21, 2015 - Even when providers aren’t forced to accept bundled payments from Medicare, which could cost them if care isn’t better and costs aren't in check, they are willing to embrace new reimbursement.
read article 

ESMO Honors Exceptional Oncologists

(ESMO) Aug 24, 2015 - The European Society for Medical Oncology (ESMO), the leading European professional organisation for advancing medical oncology, announced today the three exceptional medical oncologists who will receive its acclaimed awards.
read press release 

LabCorp Furthers Leadership in Personalized Medicine in Cancer by Offering Innovative VistaSeq® Hereditary Cancer Panel

(Yahoo! Finance) Aug 25, 2015 - Laboratory Corporation of America® Holdings announced today the nationwide availability of its VistaSeq Hereditary Cancer Panel, a novel, 27-gene panel designed to identify patients with increased risk of breast, ovarian, melanoma, pancreatic, colorectal, endometrial, gastric, prostate, and other cancers.
read article 

Medical Advances Keep Me Running

(TheHill/Congress Blog) Aug 20, 2015 - I love my doctors at the Mayo Clinic clinic, but I’m concerned that some of the experts have gone too far in the journal Mayo Clinic Proceedings with a commentary challenging the price of pharmaceuticals to treat cancer.
read article 

Aetna and UChicago Medicine Launch Oncology Medical Home

(AIS Health/Health Business Daily) Aug 25, 2015 - Aetna Inc.’s latest value-based care arrangement is an oncology medical home with the University of Chicago Medicine that started July 1. As the insurer continues its transition from a fee-for-service approach, the groups hope to impact increasing health care costs, inefficient care and redundant services.
read article 

NCCN Publishes a Resource-Stratified Framework of Clinical Practice Guidelines for Cervical Cancer

(NCCN) Aug 24, 2015 - The National Comprehensive Cancer Network® (NCCN®) has published the NCCN Framework for Resource Stratification of NCCN Guidelines (NCCN Framework™) for Cervical Cancer.
read press release 

Factbox: Top 10 Makers Of Prescription Cancer Drugs

(Yahoo!News/Reuters) Aug 21, 2015 - A leading group of U.S. cancer specialists will soon offer doctors a tool comparing the relative value of treatments, including the first direct assessment of how affordable a drug is given its benefits.
read article 

Same Day Cancer Treatment By 2020? Data Scientists Think So

(Forbes) Aug 21, 2015 - This decade, smart data could mean people with cancer receive tailored treatment from the day they are diagnosed. Are the scientists right?
read article 

AstraZeneca Appoints Roche’s Sean Bohen as Chief Medical Officer

(Bloomberg) Aug 24, 2015 - AstraZeneca Plc hired Sean Bohen as chief medical officer, poaching a cancer drug expert from Roche Holding AG’s Genentech division to lead its efforts to find new treatments.
read article 

Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib (BMN 673), a Potent PARP Inhibitor, From BioMarin

(StreetInsider) Aug 24, 2015 - Medivation, Inc. and BioMarin Pharmaceutical Inc. announced today that they have entered into an asset purchase agreement under which Medivation will acquire all worldwide rights to talazoparib (formerly referred to as BMN 673), a highly-potent, orally-available poly ADP ribose polymerase (PARP) inhibitor currently in a Phase 3 study for the treatment of patients with deleterious germline BRCA 1 or BRCA 2 mutations and locally advanced and/or metastatic breast cancer.
read article 

AstraZeneca and Peregrine Pharmaceuticals to Collaborate on Immuno-Oncology Combination Clinical Trial

(AstraZeneca) Aug 24, 2015 - Collaboration to focus on cancer immunotherapy combination of Peregrine’s ps-targeting bavituximab and AstraZeneca’s PD-L1 Inhibitor MEDI4736.
read corporate press release 

Epizyme Announces Acceptance of Investigational New Drug Application for Tazemetostat in Patients with INI1-Negative Tumors or Synovial Sarcoma

(Benzinga) Aug 24, 2015 - Epizyme, Inc., a clinical stage biopharmaceutical company creating novel epigenetic therapies for patients with cancer, today announced the U.S. Food and Drug Administration (FDA) has accepted the company's investigational new drug (IND) application for tazemetostat for the treatment of adults and pediatric patients with INI1-negative tumors or synovial sarcoma.
read article 

Orbus Gets $32.5M To Repurpose Hirsutism Drug For Brain Cancer

(MedCity News) Aug 21, 2015 - An already-approved drug used to treat excess facial hair and sleeping sickness may have an important new purpose: Treating brain cancer.
read article (free registration required) 

MTG Biotherapeutics Announces that MTG-201 was Granted Orphan Drug Designation by the US FDA for the Treatment of Malignant Mesothelioma

(TheStreet) Aug 21, 2015 - MTG Biotherapeutics today announced that the US Food and Drug Administration has granted Orphan Drug Designation for MTG-201, an advanced biologic therapy targeting Dickkopf-3 gene defects in various cancers, for the treatment of malignant mesothelioma.
read article 

ImmunoCellular Therapeutics Issues Letter to Shareholders, Highlighting Progress on Advancing ICT-107 to Phase 3 Registrational Trial

(ImmunoCellular) Aug 21, 2015 - ImmunoCellular Therapeutics, Ltd. today issued the following letter to shareholders.
read corporate press release 

Galena Biopharma Announces Independent Data Safety Monitoring Committee Recommends Reduction of Cardiac Toxicity Monitoring for NeuVax(TM) PRESENT Trial

(TheStreet) Aug 24, 2015 - Galena Biopharma, Inc. today announced that the Independent Data Monitoring Committee (IDMC) has recommended to the Company that it can reduce the cardiac toxicity monitoring for patients in its NeuVax™ (nelipepimut-S) Phase 3 PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVaxTreatment) clinical trial.
read article 

FDA Grants Breakthrough Therapy Designation to Exelixis’ Cabozantinib for the Treatment of Renal Cell Carcinoma in Patients Who Received One Prior Therapy

(Yahoo! Finance) Aug 24, 2015 - Exelixis, Inc. today announced the U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy Designation to cabozantinib, Exelixis’ lead compound, as a potential treatment for patients with advanced renal cell carcinoma (RCC) who have received one prior therapy.
read article 

FDA Extends Use Of Promacta In Young Children With Rare Blood Disorder

( Aug 24, 2015 - The U.S. Food and Drug Administration today approved Promacta (eltrombopag) to treat low blood platelet count in pediatric patients – ages one year and older – with a rare blood disorder called chronic immune thrombocytopenic purpura (ITP).
read press release 

Helix BioPharma Corp. Announces Upcoming Presentation of L-DOS47 at World Conference on Lung Cancer

(MarketWired) Aug 23, 2015 - Helix BioPharma Corp. today announced that an abstract for its lead lung cancer candidate L-DOS47 has been selected for oral presentation at the 16th World Conference on Lung Cancer (WCLC) held in Denver, Colorado, September 6-9, 2015.
read article 

Five Prime Therapeutics Announces Oral Presentation of Initial Data From Ongoing Phase 1b Trial of FP-1039/GSK3052230 in Squamous Non Small Cell Lung Cancer and Mesothelioma at World Conference on Lung Cancer

(MarketWatch) Aug 23, 2015 - Five Prime Therapeutics, Inc. today announced that initial data from GlaxoSmithKline (GSK)'s ongoing Phase 1b trial of FP-1039/GSK3052230, an FGF ligand trap, in patients with squamous non small cell lung cancer (sqNSCLC) and mesothelioma will be featured in an oral presentation by study investigators during the upcoming World Conference on Lung Cancer 2015 in Denver (September 6-9, 2015).
read article 

Data From METEOR Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma Accepted as Late-Breaker Presentation in Presidential Session at European Cancer Congress 2015

(MarketWatch) Aug 24, 2015 - Exelixis, Inc. today announced that data from clinical trials of cabozantinib and cobimetinib will be the subject of three presentations at the European Cancer Congress (ECC) 2015, which will be held September 25-29, 2015, in Vienna, Austria.
read article 

Blood Vessel Cells Help Tumours Evade The Immune System

(Karolinska Institutet [Stockholm, Sweden]) Aug 24, 2015 - A study by researchers at Karolinska Institutet is the first to suggest that cells in the tumour blood vessels contribute to a local environment that protects the cancer cells from tumour-killing immune cells. The results can contribute to the development of better immune-based cancer therapies.
read article 

Children’s Hospitals Shift from CT Scans for Common Childhood Health Problems

(Cincinnati Children’s) Aug 24, 2015 - A study published online Aug. 24 by the journal Pediatrics finds a significant decrease in the use of computed tomography (CT) scans at children’s hospitals for 10 common childhood diagnoses including seizure, concussion, appendectomy and upper respiratory tract infection.
read press release 

Clinical Trials OK for High-Grade Glioma Patients

(MedPage Today) Aug 21, 2015 - Patients with high-grade gliomas (HGG) who meet standard eligibility criteria may be good candidates for solid tumor phase I studies with single-agent molecular or cytotoxic drugs, a multi-institutional pooled analysis of Phase I oncology studies has shown.
read article (free registration required) 

Advanced Basal Cell Cancer: Think Older, Sicker

(MedPage Today) Aug 21, 2015 - Locally advanced and metastatic basal cell carcinoma (BCC) remain uncommon but tend to cluster in older, sicker patients, an analysis of a large insurance claims database showed.
read article (free registration required)